Kaifeng 155 Hospital

Kaifeng 155 Hospital, formerly the 155th Central Hospital of the People's Liberation Army, is a comprehensive tertiary medical and research institution located in Kaifeng, Henan Province, China. In August 2022, the hospital was officially transferred to the China RongTong Medical Healthcare Group, a state-owned enterprise managing former military assets. The hospital provides a wide range of clinical services, with specialized expertise in urology, cardiology, and oncology. It is actively engaged in translational research, particularly in the fields of stem cell therapy, antibody drug engineering, and novel cancer treatments in collaboration with Henan University. Notable research areas include the development of CBP/p300 inhibitors for prostate cancer and the application of advanced surgical technologies such as blue laser resection and robot-assisted reconstruction.